TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01158820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine load
Description: Ketamine 30 mg bolus prior to bronchoscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam load
Description: 2 mg bolus prior to bronchoscopy
Study: NCT00901992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEDIAS 2 ICT
Description: MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current ICT program (ACC-ICT)
Description: This program is conducted in 10 lessons in a group setting (4-8 participants)
Study: NCT03887312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: t-CETA
Description: Cognitive Behavioural Therapy (CBT) based approach delivered over the telephone. Components are available for common problems, including anxiety, depression, PTSD, conduct problems, substance abuse, and safety issues (including self-harm or suicidal ideation), and a tailored treatment package is produced for each child based on the presenting problem(s) and response to treatment. There are components for use with both child and caregiver.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Médecins du Monde treatment as usual
Description: Case manager-led care, with referral to a psychotherapist or psychiatrist as necessary. Médecins du Monde's approach is based on a joint collaboration between mental health trained case managers (who undergo extensive training by experts in the field on topics including Psychological First Aid, Child Protection, Gender Based Violence, etc.) and psychotherapists from different schools (providing Eye Movement Desensitization and Reprocessing \[EMDR\] for trauma, Interpersonal Therapy \[IPT\] for depression, Cognitive Behavioural Therapy \[CBT\], motivational counselling, familial or systemic therapy, and integrative approaches). Thus the number and content of sessions, and the person delivering treatment (case manager, psychotherapist, psychiatrist) vary.
Study: NCT00833001

Intervention type: DEVICE
Intervention: GYNECARE PROLIFT+M* Pelvic Floor Repair System
Description: Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
Study: NCT04182282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARES Dementia-Friendly Hospitals Online Training and Certification Program
Description: The CARES Dementia-Friendly Hospitals Online Training program is a 4-course, 16-module, video-based training program for hospital staff members. The CARES Dementia-Friendly Hospitals Online Certification Program is a 100-point certification exam evaluating knowledge from the online training protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARES Dementia-Friendly Hospitals Online Training and Certification Program
Description: The CARES Dementia-Friendly Hospitals Online Training program is a 4-course, 16-module, video-based training program for hospital staff members. The CARES Dementia-Friendly Hospitals Online Certification Program is a 100-point certification exam evaluating knowledge from the online training protocol.
Study: NCT03279692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
Study: NCT00795184

Intervention type: DEVICE
Group type: OTHER
Intervention: HDWLE

Intervention type: DEVICE
Group type: OTHER
Intervention: pCLE
Study: NCT00405275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: baseline methotrexate is maintained throughout the study and is not provided by the sponsor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: baseline methotrexate is maintained throughout the study and is not provided by the sponsor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: sulfasalazine, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: hydroxychloroquine, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, triple
Description: Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, etanercept
Description: Participants in triple arm (Arm 2) were given placebo etanercept injections.
Study: NCT03726749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is an anti-inflammatory medication
Study: NCT02518568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0355
Description: Oral administration (2 tablets)
Study: NCT04297176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin-traditional dosing
Description: The dose is calculated based on 2 vancomycin serum levels
Study: NCT03741699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-treatment with rLH (Luveris 75 IU),
Description: Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
Study: NCT03671889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Brain Barrier (BBB) Disruption
Description: Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
Study: NCT03803787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Description: Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Description: Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
Study: NCT01058772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INDUCTION of LABOUR
Description: Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score \< 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
Study: NCT01145508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilimogene Galvacirepvec
Description: Given SC
Study: NCT04297176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin- Trough-only based dosing
Description: The dose is calculated based on 1 vancomycin serum level (i.e. trough)
Study: NCT01711892

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Soccer training
Study: NCT03638544

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reduced gluten bread and Pasta compared o normal gluten bread and Pasta
Description: Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reduced gluten bread and Pasta compared o normal gluten bread and Pasta
Description: Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
Study: NCT02621749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal replacement therapy
Description: Patients receive renal replacement therapy according to institutional standards

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal replacement therapy
Description: Patients receive renal replacement therapy according to institutional standards
Study: NCT04123561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TLC599
Description: TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599
Description: TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSP
Description: Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% normal saline
Study: NCT00394277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 180 µg sc weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 180 µg sc weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1200 mg po daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1200 mg po daily for 48 weeks
Study: NCT01158820

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl load
Description: 50 µg bolus prior to bronchoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine maintenance
Description: 0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
Study: NCT00446901

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Selenium
Description: Selenized yeast, 300 ug/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: Selenized yeast, 300 ug/day
Study: NCT00049530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
Study: NCT04008849

Intervention type: OTHER
Intervention: Safety and efficacy assessments
Description: Long term safety and clinical outcomes
Study: NCT01371383

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Description: EPA 1680 mg/d + DHA 880 mg/d
Study: NCT00795184

Intervention type: DEVICE
Group type: OTHER
Intervention: pCLE
Study: NCT04379557

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
Study: NCT01371383

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Soybean oil
Study: NCT03292159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active RAVANS concurrent with arm motor training
Description: Patient receives non-painful, sensory-level stimulation to the skin of left outer ear, where nerve endings of the auricular branch of the vagus nerve reside, while participating in arm motor training
Study: NCT04379557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
Study: NCT04595461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Education
Description: Patients receive four short YouTube videos explaining chronic rhinosinusitis and endoscopic sinus surgery
Study: NCT01158820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine maintenance
Description: 8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam demand
Description: 0.5 mg demand bolus at discretion of pulmonologist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam demand
Description: 0.5 mg demand bolus at discretion of pulmonologist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl demand
Description: 12.5 µg demand bolus at discretion of pulmonologist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl demand
Description: 12.5 µg demand bolus at discretion of pulmonologist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benadryl demand
Description: 25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benadryl demand
Description: 25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
Study: NCT01849692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESBA1008 solution
Description: Intravitreal injection or infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESBA1008 solution
Description: Intravitreal injection or infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESBA1008 solution
Description: Intravitreal injection or infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESBA1008 solution
Description: Intravitreal injection or infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection
Study: NCT03914430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)
Study: NCT02308592

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Patient Decision Aid
Description: The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Resource Sheet
Description: Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Resource Sheet
Description: Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization.
Study: NCT04589234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmonella-IL2
Description: Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmonella-IL2
Description: Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX Alone (Historical Controls)
Description: We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Abraxane Alone (Historical Controls)
Description: We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
Study: NCT00394277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
Study: NCT03292159

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive RAVANS concurrent with arm motor training
Description: Patient does not receive stimulation delivered to the skin of left outer ear while participating in arm motor training
Study: NCT03786718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-facing Diabetes Dashboard
Description: The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.
Study: NCT03193073

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: detailed echocardiography
Description: Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
Study: NCT03833115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal gel containing or not sodium lauryl sulfate
Description: Prevention
Study: NCT01849575

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2-4 weeks a follow-up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period.
Study: NCT05007899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Alternate day dosing of ferrous sulfate
Study: NCT03861351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini WELL Toric Ready intraocular lens
Description: The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
Study: NCT03193073

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: detailed echocardiography
Description: Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum fibroblast growth factor-23
Description: serum levels of FGF-23

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum fibroblast growth factor-23
Description: serum levels of FGF-23

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: flow mediated dilatation of forearm
Description: superficial sonar assess the diameter of brachial vessel on exposure to stress

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: flow mediated dilatation of forearm
Description: superficial sonar assess the diameter of brachial vessel on exposure to stress